Ents. Prospective, randomized Phase III studies are needed to determine whether certain drugs GSK2126458 PI3K inhibitor at best as a single agent or in combination medications should be used and the weight Be selected. Cross-resistance to platinum agents and 5-fluorouracil Most of the studies used here say nothing, as second-line combination chemotherapy plans. Platinum agents were at the h Ufigsten used as part of combination therapy. It is reasonable, a platinum drug for patients who have not previously been exposed to view on these funds. However, when cisplatin was used again as part of combination therapy, it was not clear whether its inclusion improved the RR. The other components of the combination therapy of platinum in the salvage therapy was Haupts Chlich of taxanes and irinotecan, have shown that the synergistic antitumor activity t in combination with platinum in vivo studies.
Cisplatin is a toxic drug causes Gamma Secretase pathway several side effects such as nausea and vomiting tenacious Storeyed failure, kidney and liver, and deafness may affect all, The quality of life T and PS patients receiving chemotherapy, second line. Although carboplatin is known to have anti-tumor activity of t against gastric cancer cell lines and in animal models of gastric cancer, he showed a marginal activity t in patients with gastric cancer, as with a RR of 610% in monotherapy. In addition, oxaliplatin has activity t shown in many tumor cell lines to cisplatin and is expected to replace cisplatin in the treatment of stomach cancer. FOLFOX as second-line therapy in patients previously treated with FP showed a moderate activity t.
5-FU is cytotoxic mechanisms which have from those of taxanes, oxaliplatin and irinotecan. It is not clear whether the 5-FU prodrug, or combinations of these agents as second-line chemotherapy are more effective than medication alone for the increased use of 5-FU and its prodrugs by major cause several side effects. Although it is difficult to compare studies with single agent or agents in combination with 5-FU, the RR of paclitaxel, a single agent, irinotecan were 4 and 19% and RR and combinations of these agents with 5-FU by 21% and 1021, respectively. Combined chemotherapy and can be used as monotherapy but combination therapy to improve the anti-tumor, then put They also addicted If, for toxicity T and produce side effects.
In non-small cell lung cancer, certain drugs such as docetaxel, pemetrexed and TKI, a drug that has a low toxicity t be tolerated and has demonstrated the advantages of survival than the second-line chemotherapy. The taxanes, irinotecan, and TS-1 were given as a single agent in second-line regimen. Weekly paclitaxel in patients with poor PS is effective and well tolerated Possible. In the studies of Japanese patients with a PS of 02, single agent paclitaxel showed an RR of 1617.5% with OS 7.88.5 of the month. Although paclitaxel doublet chemotherapy with fluoropyrimidines or platinum compounds produced modest improvements in tumor response and prognosis, as a doublet therapy leads to more complications than therapy paclitaxel alone. In order to reduce the toxicity of t, k Nnte split-dose combination chemotherapy should be considered. With regard to the timing of administration of paclitaxel, w Chentliche injection also seemed less toxicity T and better results than administration every 3 weeks to show. Docetaxel is also